ReviewTherapeutic advances in chronic disease2016
Gout: optimizing treatment to achieve a disease cure.
Review in Therapeutic advances in chronic disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.Annals of the rheumatic diseases · 2017Pooled it
- Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout.Arthritis & rheumatology (Hoboken, N.J.) · 2024Trial
- Spatiotemporal immune gradients in gout: immune response-driven activation of the NLRP3-IL-1β axis and its transition to trained immunity.Frontiers in immunology · 2026Review
- Quality Care Assessment in Gout.Current rheumatology reports · 2025Review
- Incident gout and weight change patterns: a retrospective cohort study of US adults.Arthritis research & therapy · 2021Article
- The Effect of Low and Moderate Exercise on Hyperuricemia: Protocol for a Randomized Controlled Study.Frontiers in endocrinology · 2021Article
- Identification of xanthine oxidase inhibitors through hierarchical virtual screening.RSC advances · 2020Article
- Systematic Structure-Activity Relationship (SAR) Exploration of Diarylmethane Backbone and Discovery of A Highly Potent Novel Uric Acid Transporter 1 (URAT1) Inhibitor.Molecules (Basel, Switzerland) · 2018Article
- Review: Gout: A Roadmap to Approaches for Improving Global Outcomes.Arthritis & rheumatology (Hoboken, N.J.) · 2017Review
- Discovery of a Flexible Triazolylbutanoic Acid as a Highly Potent Uric Acid Transporter 1 (URAT1) Inhibitor.Molecules (Basel, Switzerland) · 2016Article
- Therapeutic Efficacy of Urinile Against Gouty Arthritis.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gout is one of the most common inflammatory arthritides. The disease is due to the deposition of monosodium urate crystals. These deposits are reversible with proper treatment, suggesting that gout is a curable disease. The main aim in gout is to lower serum uric acid levels to a pre-established target; there are different urate-lowering drugs (xanthine oxidase inhibitors, uricosurics and uricases) through which this can be achieved. Proper treatment of gout also involves correct management of acute flares and their prevention. To ensure treatment adherence it is necessary to explain to the patient what the objectives are.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.